These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16159570)

  • 1. [Clinical observation on treatment of IgA nephropathy with Huobahuagen Tablets and irbesartan].
    Guan XD; Wu YF; Zhao W
    Zhong Xi Yi Jie He Xue Bao; 2005 Sep; 3(5):366-9. PubMed ID: 16159570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical observation of treating early diabetic nephropathy by qi supplementing, yin nourishing, blood stasis dispersing, collateral dredging recipe].
    Wang FL; Chen ZQ; Wang YH
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jan; 32(1):35-8. PubMed ID: 22500388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic nephropathy: study protocol for a randomized, double-blind and placebo-controlled clinical trial.
    Wang H; Mu W; Zhai J; Xing D; Miao S; Wang J; Deng Y; Wang N; Chen H; Yang H; He X; Shang H
    Trials; 2013 Jun; 14():165. PubMed ID: 23738508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy.
    Remuzzi A; Perico N; Sangalli F; Vendramin G; Moriggi M; Ruggenenti P; Remuzzi G
    Am J Physiol; 1999 Mar; 276(3):F457-66. PubMed ID: 10070170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy and safety of high-dose irbesartan in treatment of clinical proteinuria in patients with chronic kidney disease].
    Li X; Chen XD; Li ZX
    Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1034-8. PubMed ID: 22333173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
    Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D-Binding Protein Is a Potential Urinary Biomarker of Irbesartan Treatment Response in Patients with IgA Nephropathy.
    Zeng J; Wen Q; Rong R; Huang F; Yang Q; Tang X; He F; Huang N; Yu X
    Genet Test Mol Biomarkers; 2016 Nov; 20(11):666-673. PubMed ID: 27603418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
    Li S; Cao B; Feng QH; Li XZ
    Zhonghua Er Ke Za Zhi; 2003 Nov; 41(11):817-21. PubMed ID: 14728886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
    Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study.
    Pozzi C; Del Vecchio L; Casartelli D; Pozzoni P; Andrulli S; Amore A; Peruzzi L; Coppo R; Locatelli F; ;
    J Nephrol; 2006; 19(4):508-14. PubMed ID: 17048209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
    Croom KF; Curran MP; Goa KL; Perry CM
    Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension].
    Sun NL; Jing S; Chen J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Jul; 33(7):618-21. PubMed ID: 16080809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Protective effects of compound shenhua tablet on diabetic nephropathy rats].
    Geng WJ; Wei RB; Mao W
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Mar; 32(3):352-5. PubMed ID: 22686082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospective, multi-centered, randomized and controlled trial on effect of Shenle Capsule in treating patients with IgA nephropathy of Fei-Pi qi-deficiency syndrome].
    Chen XM; Chen YP; Zhou ZL
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 Dec; 26(12):1061-5. PubMed ID: 17205814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of primary chronic glomerulonephritis with Rehmannia glutinosa acteosides in combination with the angiotensin receptor blocker irbesartan: a randomized controlled trial.
    Qiu H; Fu P; Fan W; Zuo C; Feng P; Shi P; Cao L; Liu F; Zhou L; Chen F; Zhong H; Gou Z; Liang Y; Shi M
    Phytother Res; 2014 Jan; 28(1):132-6. PubMed ID: 23519822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
    Coronel F; Cigarrán S; García-Mena M; Herrero JA; Calvo N; Pérez-Flores I
    Nefrologia; 2008; 28(1):56-60. PubMed ID: 18336132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.